Advanced search
Publication Cover
Expert Opinion on Investigational Drugs Volume 17, 2008 - Issue 11
Submit an article Journal homepage
670
Views
59
CrossRef citations to date
0
Altmetric
Review

Novel bone cancer drugs: investigational agents and control paradigms for primary bone sarcomas (Ewing's sarcoma and osteosarcoma)

Pete Anderson University of Texas, MD Anderson Cancer Center, Department of Pediatrics, 1515 Holcombe Blvd, Unit 87, Houston, TX 77030-4009, USA +1 713 563 0893; +1 713 794 5042; [email protected]
, MD PhD,
Lisa Kopp University of Texas, MD Anderson Cancer Center, Department of Pediatrics, 1515 Holcombe Blvd, Unit 87, Houston, TX 77030-4009, USA +1 713 563 0893; +1 713 794 5042; [email protected]
, DO,
Nicholas Anderson New York Medical College, School of Medicine, Valhalla, NY 10595, USA
,
Kathleen Cornelius University of Texas, MD Anderson Cancer Center, Department of Pediatrics, 1515 Holcombe Blvd, Unit 87, Houston, TX 77030-4009, USA +1 713 563 0893; +1 713 794 5042; [email protected]
,
Cynthia Herzog University of Texas, MD Anderson Cancer Center, Department of Pediatrics, 1515 Holcombe Blvd, Unit 87, Houston, TX 77030-4009, USA +1 713 563 0893; +1 713 794 5042; [email protected]
, MD,
Dennis Hughes University of Texas, MD Anderson Cancer Center, Department of Pediatrics, 1515 Holcombe Blvd, Unit 87, Houston, TX 77030-4009, USA +1 713 563 0893; +1 713 794 5042; [email protected]
, MD PhD &
Winston Huh University of Texas, MD Anderson Cancer Center, Department of Pediatrics, 1515 Holcombe Blvd, Unit 87, Houston, TX 77030-4009, USA +1 713 563 0893; +1 713 794 5042; [email protected]
, MD show all
Pages 1703-1715 | Published online: 15 Oct 2008

Citations (59)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (9)

Deepam Pushpam, Vikas Garg, Sandip Ganguly & Bivas Biswas. (2020) Management of Refractory Pediatric Sarcoma: Current Challenges and Future Prospects. OncoTargets and Therapy 13, pages 5093-5112.
Read now
David Van Mater & Lars Wagner. (2019) Management of recurrent Ewing sarcoma: challenges and approaches. OncoTargets and Therapy 12, pages 2279-2288.
Read now
E. Palmerini, R. L. Jones, E. Setola, P. Picci, E. Marchesi, R. Luksch, G. Grignani, M. Cesari, A. Longhi, M. E. Abate, A. Paioli, Z. Szucs, L. D’ambrosio, K. Scotlandi, F. Fagioli, S. Asaftei & S. Ferrari. (2018) Irinotecan and temozolomide in recurrent Ewing sarcoma: an analysis in 51 adult and pediatric patients. Acta Oncologica 57:7, pages 958-964.
Read now
Nilgun Kurucu, Neriman Sari & Inci Ergurhan Ilhan. (2015) Irinotecan and Temozolamide Treatment for Relapsed Ewing Sarcoma: A Single-Center Experience and Review of the Literature. Pediatric Hematology and Oncology 32:1, pages 50-59.
Read now
Kosei Ando, Kanji Mori, Nedège Corradini, Françoise Redini & Dominique Heymann. (2011) Mifamurtide for the treatment of nonmetastatic osteosarcoma. Expert Opinion on Pharmacotherapy 12:2, pages 285-292.
Read now
Claudia Maria Hattinger, Michela Pasello, Stefano Ferrari, Piero Picci & Massimo Serra. (2010) Emerging drugs for high-grade osteosarcoma. Expert Opinion on Emerging Drugs 15:4, pages 615-634.
Read now
Keiichi Masuya & Naoki Teno. (2010) Small molecules for bone diseases. Expert Opinion on Therapeutic Patents 20:4, pages 563-582.
Read now
Dennis PM Hughes. (2009) Strategies for the targeted delivery of therapeutics for osteosarcoma. Expert Opinion on Drug Delivery 6:12, pages 1311-1321.
Read now
Paul A Meyers. (2009) Muramyl tripeptide (mifamurtide) for the treatment of osteosarcoma. Expert Review of Anticancer Therapy 9:8, pages 1035-1049.
Read now

Articles from other publishers (50)

Pengru Wang, Bo Li, Shangbin Zhou, Yingye Xin, Zhipeng Zhu, Shujie Duan, Danyang Bai, Hao Yuan, Wei Xu & Jianru Xiao. (2023) Efficacy and safety of COVID-19 vaccines for patients with spinal tumors receiving denosumab treatment: An initial real−clinical experience study. Frontiers in Oncology 13.
Crossref
Emily K. Slotkin & Paul A. Meyers. (2022) Irinotecan dose schedule for the treatment of Ewing sarcoma. Pediatric Blood & Cancer 70:1.
Crossref
Bi-Cheng Wang, Bo-Ya Xiao & Guo-He Lin. (2022) Irinotecan plus temozolomide in relapsed Ewing sarcoma: an integrated analysis of retrospective studies. BMC Cancer 22:1.
Crossref
Ana Patiño-García & Fernando Lecanda. 2022. Bone Cancer. Bone Cancer 591 604 .
Jose Duran Moreno, Georgios Papageorgiou, Ioanna Gazouli & Anastasios Kyriazoglou. (2021) Systemic Treatment of Ewing Sarcoma: Current Options and Future Perspectives. Forum of Clinical Oncology 12:3, pages 3-27.
Crossref
O. M. Romantsova, D. V. Nisichenko, D. B. Khestanov, V. V. Khairullova, A. Z. Dzampaev & K. I. Kirgizov. (2021) Treatment of Ewingʼs sarcoma in children and adolescents: new vision. Russian Journal of Pediatric Hematology and Oncology 8:3, pages 30-42.
Crossref
Sebastian Dorin Asaftei, Nadia Puma, Anna Paioli, Marco Petraz, Carlo Morosi, Marta Podda, Angela Tamburini, Emanuela Palmerini, Luca Coccoli, Giovanni Grignani, Carla Manzitti, Rossella Bertulli, Francesco De Leonardis, Marco Rabusin, Anna Campello, Elisa Tirtei, Piero Picci, Arcangelo Prete, Alessandra Longhi, Franca Fagioli & Roberto Luksch. (2021) Front-Line Window Therapy with Temozolomide and Irinotecan in Patients with Primary Disseminated Multifocal Ewing Sarcoma: Results of the ISG/AIEOP EW-2 Study. Cancers 13:12, pages 3046.
Crossref
Arthur Wingerter, Khalifa El Malki, Roger Sandhoff, Larissa Seidmann, Daniel-Christoph Wagner, Nadine Lehmann, Nadine Vewinger, Katrin B. M. Frauenknecht, Clemens J. Sommer, Frank Traub, Thomas Kindler, Alexandra Russo, Henrike Otto, André Lollert, Gundula Staatz, Lea Roth, Claudia Paret & Jörg Faber. (2021) Exploiting Gangliosides for the Therapy of Ewing’s Sarcoma and H3K27M-Mutant Diffuse Midline Glioma. Cancers 13:3, pages 520.
Crossref
A. F. Bykova, I. M. Ivanov & A. N. Grebenyuk. (2018) PROBLEMS AND PROSPECTS OF INHALATION APPLICATION OF PEPTIDE AND PROTEIN COMPOUNDS AS POTENTIAL MEDICAL RADIATION PROTECTIVE AGENTS. Medicо-Biological and Socio-Psychological Problems of Safety in Emergency Situations:2, pages 60-69.
Crossref
Annie Schmid-Alliana, Heidy Schmid-Antomarchi, Rasha Al-Sahlanee, Patricia Lagadec, Jean-Claude Scimeca & Elise Verron. (2018) Understanding the Progression of Bone Metastases to Identify Novel Therapeutic Targets. International Journal of Molecular Sciences 19:1, pages 148.
Crossref
Damon R. Reed, Masanori Hayashi, Lars Wagner, Odion Binitie, Diana A. Steppan, Andrew S. Brohl, Eric T. Shinohara, Julia A. Bridge, David M. Loeb, Scott C. Borinstein & Michael S. Isakoff. (2017) Treatment pathway of bone sarcoma in children, adolescents, and young adults. Cancer 123:12, pages 2206-2218.
Crossref
Peter M. Anderson. 2017. Immunotherapy. Immunotherapy 127 140 .
Peter M. Anderson, Stefan S. Bielack, Richard G. Gorlick, Keith Skubitz, Najat C. Daw, Cynthia E. Herzog, Odd R. Monge, Alvaro Lassaletta, Erica Boldrini, Zsuzanna Pápai, Joseph Rubino, Kumudu Pathiraja, Darcy A. Hille, Mark Ayers, Siu‐Long Yao, Michael Nebozhyn, Brian Lu & David Mauro. (2016) A phase II study of clinical activity of SCH 717454 (robatumumab) in patients with relapsed osteosarcoma and Ewing sarcoma. Pediatric Blood & Cancer 63:10, pages 1761-1770.
Crossref
Françoise Redini & Dominique Heymann. (2015) Bone Tumor Environment as a Potential Therapeutic Target in Ewing Sarcoma. Frontiers in Oncology 5.
Crossref
Ming Dong, Jinghao Liu, Zuoqing Song, Xin Li, Tao Shi, Dan Wang, Dian Ren & Jun Chen. (2015) Primary Multiple Pulmonary Primitive Neuroectodermal Tumor. Medicine 94:27, pages e1136.
Crossref
Santosh Valvi & Stewart J Kellie. (2015) Ewing Sarcoma: Focus on Medical Management. Journal of Bone and Soft Tissue Tumors 1:1, pages 8-17.
Crossref
Ana Patiño-García & Fernando Lecanda. 2015. Bone Cancer. Bone Cancer 223 234 .
Joanne Lagmay & Nicholas D. Yeager. 2015. Malignant Pediatric Bone Tumors - Treatment & Management. Malignant Pediatric Bone Tumors - Treatment & Management 221 263 .
Peter F. M. Choong. (2014) New Medical/Biologic Paradigms in the Treatment of Bone Tumors. Current Surgery Reports 2:6.
Crossref
Daniela Egas-Bejar, Pete M. Anderson, Rishi Agarwal, Fernando Corrales-Medina, Eswaran Devarajan, Winston W. Huh, Robert E Brown & Vivek Subbiah. (2014) Theranostic profiling for actionable aberrations in advanced high risk osteosarcoma with aggressive biology reveals high molecular diversity: the human fingerprint hypothesis. Oncoscience 1:2, pages 167-179.
Crossref
Randala Hamdan, Zhichao Zhou & Eugenie S. Kleinerman. (2014) Blocking SDF-1α/CXCR4 Downregulates PDGF-B and Inhibits Bone Marrow–Derived Pericyte Differentiation and Tumor Vascular Expansion in Ewing Tumors. Molecular Cancer Therapeutics 13:2, pages 483-491.
Crossref
Rincy Jimmy, Sarahlouise White & Karolina Lisy. (2014) Effectiveness of mifamurtide in addition to standard chemotherapy for high-grade osteosarcoma: a systematic review protocol. JBI Database of Systematic Reviews and Implementation Reports 12:11, pages 61-73.
Crossref
Evandro M. Alexandrino, Sandra Ritz, Filippo Marsico, Grit Baier, Volker Mailänder, Katharina Landfester & Frederik R. Wurm. (2014) Paclitaxel-loaded polyphosphate nanoparticles: a potential strategy for bone cancer treatment. Journal of Materials Chemistry B 2:10, pages 1298.
Crossref
Kosei Ando, Marie-Françoise Heymann, Verena Stresing, Kanji Mori, Françoise Rédini & Dominique Heymann. (2013) Current Therapeutic Strategies and Novel Approaches in Osteosarcoma. Cancers 5:4, pages 591-616.
Crossref
Zuzana Tatar, Emilie Thivat, Eloise Planchat, Pierre Gimbergues, Emilie Gadea, Catherine Abrial & Xavier Durando. (2013) Temozolomide and unusual indications: Review of literature. Cancer Treatment Reviews 39:2, pages 125-135.
Crossref
Nicole D. RiddleKrister JonesArthur P. StaddonJohn S. Brooks. (2013) “Residual Osteocytic Lesion”: Effect of Denosumab (AMG 162) Treatment on the Morphology and Immunophenotype of Giant-Cell Tumor. JBJS Case Connector 3:1, pages e10.
Crossref
J PosthumaDeBoer, B.J van Royen & M.N Helder. (2013) Mechanisms of therapy resistance in osteosarcoma: a review. Oncology Discovery 1:1, pages 8.
Crossref
Beverly A. Teicher. (2012) Searching for molecular targets in sarcoma. Biochemical Pharmacology 84:1, pages 1-10.
Crossref
Jantine PosthumaDeBoer, Thomas Würdinger, Harm CA Graat, Victor W van Beusechem, Marco N Helder, Barend J van Royen & Gertjan JL Kaspers. (2011) WEE1 inhibition sensitizes osteosarcoma to radiotherapy. BMC Cancer 11:1.
Crossref
Jakob K. Anninga, Hans Gelderblom, Marta Fiocco, Judith R. Kroep, Antoni H.M. Taminiau, Pancras C.W. Hogendoorn & R. Maarten Egeler. (2011) Chemotherapeutic adjuvant treatment for osteosarcoma: Where do we stand?. European Journal of Cancer 47:16, pages 2431-2445.
Crossref
Nadezhda V. Koshkina, Krithi Rao‐Bindal & Eugenie S. Kleinerman. (2011) Effect of the histone deacetylase inhibitor SNDX‐275 on Fas signaling in osteosarcoma cells and the feasibility of its topical application for the treatment of osteosarcoma lung metastases. Cancer 117:15, pages 3457-3467.
Crossref
J. PosthumaDeBoer, M. A. Witlox, G. J. L. Kaspers & B. J. van Royen. (2011) Molecular alterations as target for therapy in metastatic osteosarcoma: a review of literature. Clinical & Experimental Metastasis 28:5, pages 493-503.
Crossref
F. Hemingway, R. Taylor, H.J. Knowles & N.A. Athanasou. (2011) RANKL-independent human osteoclast formation with APRIL, BAFF, NGF, IGF I and IGF II. Bone 48:4, pages 938-944.
Crossref
Beverly A. Teicher, Rebecca G. Bagley, Cecile Rouleau, Ariel Kruger, Yi Ren & Leslie Kurtzberg. (2011) Characteristics of human Ewing/PNET sarcoma models. Annals of Saudi Medicine 31:2, pages 174-182.
Crossref
Lars Wagner. (2011) Camptothecin-Based Regimens for Treatment of Ewing Sarcoma: sPast Studies and Future Directions. Sarcoma 2011, pages 1-9.
Crossref
Vivek Subbiah & Pete Anderson. (2011) Targeted Therapy of Ewing's Sarcoma. Sarcoma 2011, pages 1-10.
Crossref
Keri S. Stewart & Eugenie S. Kleinerman. (2011) Tumor Vessel Development and Expansion in Ewing's Sarcoma: A Review of the Vasculogenesis Process and Clinical Trials with Vascular-Targeting Agents. Sarcoma 2011, pages 1-7.
Crossref
Amalia Conti, Gemma Caballero Rodriguez, Antonella Chiechi, Rosa Maria Dégano Blazquez, Victoria Barbado, Tibor Krènacs, Chiara Novello, Laura Pazzaglia, Irene Quattrini, Licciana Zanella, Piero Picci, Enrique De Alava & Maria Serena Benassi. (2011) Identification of Potential Biomarkers for Giant Cell Tumor of Bone Using Comparative Proteomics Analysis. The American Journal of Pathology 178:1, pages 88-97.
Crossref
Colin Moore, Don Eslin, Alejandro Levy, Jessica Roberson, Vincent Giusti & Robert Sutphin. (2010) Prognostic significance of early lymphocyte recovery in pediatric osteosarcoma. Pediatric Blood & Cancer 55:6, pages 1096-1102.
Crossref
Ann O. Karosas. (2010) Ewing’s sarcoma. American Journal of Health-System Pharmacy 67:19, pages 1599-1605.
Crossref
Guillaume A. Odri, Sophie Dumoucel, Gaëlle Picarda, Séverine Battaglia, François Lamoureux, Nadège Corradini, Julie Rousseau, Franck Tirode, Karine Laud, Olivier Delattre, François Gouin, Dominique Heymann & Françoise Redini. (2010) Zoledronic Acid as a New Adjuvant Therapeutic Strategy for Ewing's Sarcoma Patients. Cancer Research 70:19, pages 7610-7619.
Crossref
Thomas B. Beckingsale & Craig H. Gerrand. (2010) (i) Osteosarcoma. Orthopaedics and Trauma 24:5, pages 321-331.
Crossref
James E. Frampton. (2010) Mifamurtide. Pediatric Drugs 12:3, pages 141-153.
Crossref
Josh Sommer, Doha M Itani, Kelly C Homlar, Vicki L Keedy, Jennifer L Halpern, Ginger E Holt, Herbert S Schwartz, Cheryl M Coffin, Michael J Kelley & Justin MM Cates. (2010) Methylthioadenosine phosphorylase and activated insulin‐like growth factor‐1 receptor/insulin receptor: potential therapeutic targets in chordoma. The Journal of Pathology 220:5, pages 608-617.
Crossref
Joseph L. Sottnik, Dawn L. Duval, E. J. Ehrhart & Douglas H. Thamm. (2010) An orthotopic, postsurgical model of luciferase transfected murine osteosarcoma with spontaneous metastasis. Clinical & Experimental Metastasis 27:3, pages 151-160.
Crossref
Denise A. Casey, Leonard H. Wexler, Melinda S. Merchant, Alexander J. Chou, Pamela R. Merola, Anita P. Price & Paul A. Meyers. (2009) Irinotecan and temozolomide for Ewing sarcoma: The Memorial Sloan‐Kettering experience. Pediatric Blood & Cancer 53:6, pages 1029-1034.
Crossref
Andrea Hayes-Jordan & Peter Anderson. (2009) Desmoplastic small round cell tumor: review of therapy including surgery followed by continuous hyperthermic peritoneal perfusion of chemotherapy. Oncology Reviews 3:3, pages 195-200.
Crossref
. (2009) Current World Literature. Current Opinion in Oncology 21:4, pages 386-392.
Crossref
Dennis PM Hughes. (2009) Novel agents in development for pediatric sarcomas. Current Opinion in Oncology 21:4, pages 332-337.
Crossref
Vivek Subbiah, Pete Anderson, Alexander J. Lazar, Emily Burdett, Kevin Raymond & Joseph A. Ludwig. (2009) Ewing’s Sarcoma: Standard and Experimental Treatment Options. Current Treatment Options in Oncology 10:1-2, pages 126-140.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.